Walvax Biotechnology (300142.SZ) Receives Approval for Clinical Trials of Freeze-Dried mRNA Vaccine Against Herpes Zoster Virus

Stock News12-12

Walvax Biotechnology Co.,Ltd. (300142.SZ) announced that its subsidiaries—Beijing Walvax Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Walvax Biotechnology Co., Ltd.—in collaboration with Fudan University and Shanghai BlueMag Biotechnology Co., Ltd. ("BlueMag Biotech"), have received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for their jointly developed freeze-dried mRNA vaccine against herpes zoster virus. After review, the application submitted on September 18, 2025, for the freeze-dried mRNA vaccine was deemed compliant with drug registration requirements, granting approval to proceed with clinical trials for the prevention of herpes zoster.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182511579?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182511579","market":"us","top_or_hot":-1,"title":"Walvax Biotechnology (300142.SZ) Receives Approval for Clinical Trials of Freeze-Dried mRNA Vaccine Against Herpes Zoster Virus","media":"Stock News","content":"<p>Walvax Biotechnology Co.,Ltd. (300142.SZ) announced that its subsidiaries—Beijing Walvax Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Walvax Biotechnology Co., Ltd.—in collaboration with Fudan University and Shanghai BlueMag Biotechnology Co., Ltd. (\"BlueMag Biotech\"), have received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration for their jointly developed freeze-dried mRNA vaccine against herpes zoster virus. After review, the application submitted on September 18, 2025, for the freeze-dried mRNA vaccine was deemed compliant with drug registration requirements, granting approval to proceed with clinical trials for the prevention of herpes zoster.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Walvax Biotechnology (300142.SZ) Receives Approval for Clinical Trials of Freeze-Dried mRNA Vaccine Against Herpes Zoster Virus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWalvax Biotechnology (300142.SZ) Receives Approval for Clinical Trials of Freeze-Dried mRNA Vaccine Against Herpes Zoster Virus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-12 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Walvax Biotechnology Co.,Ltd. (300142.SZ) announced that its subsidiaries—Beijing Walvax Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Walvax Biotechnology Co., Ltd.—in collaboration with Fudan University and Shanghai BlueMag Biotechnology Co., Ltd. (\"BlueMag Biotech\"), have received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration for their jointly developed freeze-dried mRNA vaccine against herpes zoster virus. After review, the application submitted on September 18, 2025, for the freeze-dried mRNA vaccine was deemed compliant with drug registration requirements, granting approval to proceed with clinical trials for the prevention of herpes zoster.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0070","symbol_name":"员工持股","start_time":0,"source_url":"","article_id":"1182511579","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182511579","pubTimestamp":1765536373,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Walvax Biotechnology Co.,Ltd. (300142.SZ) announced that its subsidiaries—Beijing Walvax Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Walvax Biotechnology Co.,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","300142":"沃森生物","BK0070":"员工持股","BK0077":"质押式回购","BK0046":"生物疫苗","BK0239":"医药制造"},"translate_title":"华维生物（300142.SZ）带状疱疹病毒冻干mRNA疫苗临床试验获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"300142":1},"content_text":"Walvax Biotechnology Co.,Ltd. (300142.SZ) announced that its subsidiaries—Beijing Walvax Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Walvax Biotechnology Co., Ltd.—in collaboration with Fudan University and Shanghai BlueMag Biotechnology Co., Ltd. (\"BlueMag Biotech\"), have received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration for their jointly developed freeze-dried mRNA vaccine against herpes zoster virus. After review, the application submitted on September 18, 2025, for the freeze-dried mRNA vaccine was deemed compliant with drug registration requirements, granting approval to proceed with clinical trials for the prevention of herpes zoster.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182511579","isCrawlerRequest":true}